Clinical Trial

Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis

Name: Beta-Lactam Antibiotics InitiaL ExpoSure OptimisEd in CriticallY Ill Patients with SEpsis — clinical trial record (NCT06766461)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: BULLSEYE

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

The aim of this study is to investigate if an initial short double dose of beta-lactam antibiotics will reduce mortality in critically ill patients with sepsis.

Trial Details

NCT Number	NCT06766461
Lead Sponsor	Erasmus Medical Center Collaborators: Maasstad Hospital, Albert Schweitzer Hospital
Conditions	Sepsis - to Reduce Mortality in the Intensive Care Unit, Sepsis, Septic Shock
Enrollment	980 participants
Start Date	2025-01-03
Primary Completion	2026-12-01 (estimated)
Study Completion	2027-12-01 (estimated)
Updated on ClinicalTrials.gov	2025-01-09